What are the risks associated with using triptans and ergotamines for the treatment of migraine?
According to a systematic review of observational studies, the use of triptans and ergotamines for the treatment of migraine has been associated with an increased risk of stroke. Other potential risks include a higher risk of ischemic stroke in women using estrogen-containing contraceptives, and a possible association between the use of calcitonin gene-related peptide inhibitor therapy and ischemic stroke.